We are pleased to complete the last subject visit in our Phase 1 trial of MBX 1416 in healthy adults and extend our sincere appreciation to the participants, investigators and clinical team for their ...
MBX Biosciences (MBX) completed the last subject’s last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the company’s long-acting glucagon-like peptide 1 receptor antagonist ...